Introduction
Early and appropriate goal-directed fluid therapy is fundamental in acute resuscitation of critically ill patients [
1,
2]; however, it is almost always associated with a certain degree of fluid overload (FO) [
3,
4], which promotes tissue edema that could potentially contribute to progressive organ dysfunction [
5,
6].
There is a growing amount of evidence supporting the relation between FO and unfavorable outcomes in critically ill patients. This has been demonstrated in general ICUs [
7] and in specific clinical settings, such as acute lung injury/acute respiratory distress syndrome (ALI/ARDS) [
8,
9], in patients undergoing abdominal surgery [
10,
11], cardiac surgery [
12] and in septic patients [
13]. With regard to acute kidney injury (AKI) in particular, multiple pediatric studies have shown that a greater FO at the time of renal replacement therapy (RRT) is associated with higher mortality [
14‐
16]. In a small study of 81 adult AKI patients who underwent RRT, a volume-related weight gain (VRWG) >10%, used as a surrogate for FO, was similarly associated with poor outcomes [
17]. An association between FO and higher mortality has also been shown in critically ill patients with less severe forms of AKI [
18‐
21]. In this context, FO has emerged as a potential 'biomarker' in critical illness, and it has been proposed that its prevention may be an important determinant of survival, particularly in AKI [
3].
Oliguria is a common situation in the ICU and is considered an early and sensitive biomarker of renal injury because it may precede a creatinine-based diagnosis of AKI [
22,
23]. Furthermore, in multicenter studies on critically ill patients with AKI, the presence of oliguria has been associated with higher mortality [
20,
24‐
26]. Indeed, the evidence points out that both FO and oliguria are important predictors of mortality in critically ill patients. Fluid accumulation is a logical and expected complication of oliguric AKI due to impaired water and sodium excretion [
20,
27]. It remains unclear whether their effects are independent of each other or if FO is merely in the causal pathway between oliguria and death. Interestingly, very few studies have adjusted for urine output in the analysis on FO and mortality. In 81 AKI patients requiring RRT, both oliguria and FO were independent predictors of mortality [
17] and in a
post hoc analysis of 306 AKI patients from the Fluid and Catheter Treatment Trial (FACTT), FO was shown to be independently associated with mortality both in oliguric and non-oliguric patients [
19]. In a large multicenter European study [
20] on critically ill patients with AKI, a positive fluid balance was an important factor associated with increased 60-day mortality, but there was no adjustment for urine volume or oliguria.
The aim of the present study is to evaluate the impact of both fluid balance and urine volume on outcomes and determine whether they behave as independent predictors of mortality in adult ICU patients with AKI.
Discussion
Using data from a multicenter ICU cohort [
28], we examined the influence of fluid balance and urine volume on outcomes among critically ill patients with AKI. The key findings of this study are: first, AKI patients had higher MFB, lower MUV, and a higher mortality than non-AKI patients; second, MFB was significantly higher in non-survivors in all AKI patients, and consistently higher across various subgroups (early and late AKI, oliguric and non-oliguric, use and non-use of diuretics, Figure
1); third, MUV was lower in non-survivors in all subgroups, except non-oliguric patients; finally, both MFB and MUV were significantly associated with increased 28-day mortality in AKI patients, and their interaction was significant as well.
Our results are consistent with prior studies on critically ill patients, both without and with AKI. In non-AKI studies, a positive fluid balance was strongly associated with increased mortality and other unfavorable outcomes in some subgroups of ICU patients, including worse lung function, longer duration of mechanical ventilation, increased post-operative complications and longer ICU stay [
7‐
13]. Among adult AKI patients in particular, Van Biesen
et al. [
21] showed that additional fluid loading not only failed to improve renal function, but was also associated with worsening of respiratory function. The Program to Improve Care in Acute Renal Disease (PICARD) group [
18] concluded that fluid weight gain >10% in AKI patients was associated with higher mortality and that the increase in mortality rate was proportional to the degree of fluid accumulation. In a study with 1,120 ICU patients with AKI, the authors showed that the MFB was an independent predictor of mortality on multivariate analysis (adjusted HR 1.21, 95%CI 1.13 to 1.28;
P <0.001) [
20]. However, these three studies did not adjust for urine volume in their models.
An important finding in the present study is that fluid balance and urine volume were both strong and significant predictors of mortality, even accounting for their interaction. We reproduced the analysis performed in AKI patients from a multicenter European ICU cohort [
20] and extended it by adding the variable urine volume to the analysis. Our findings confirmed the association of both FO (adjusted HR per L/day of MFB 1.67, 95%CI 1.33 to 2.09;
P <0.001) and reduced urine volume (adjusted HR per L/day of MUV 0.47, 95%CI 0.33 to 0.67;
P <0.001) with adverse outcomes. Qualitatively similar findings were obtained even when the urine volume was expressed as the presence of oliguria or duration of oliguria, implying that FO is not merely an intermediate in the pathway between lower urine output and mortality. This relation is not well-explored in the literature. To our knowledge, only two adult AKI studies have adjusted for urine output in their analysis of FO and outcomes. In a cohort of 81 adult critically ill patients with severe AKI requiring RRT, the authors examined the effect of oliguria, VRWG used as a measure of FO, sepsis and APACHE II score in the multivariate model [
17]. Both oliguria and VRWG ≥10% were predictors of 30-day mortality (adjusted odds ratio (OR) 3.04, 95%CI 1.10 to 8.36 and adjusted OR 2.71, 95%CI 1.05 to 6.99, respectively). In the aforementioned FACTT study, the association between fluid balance and mortality was significant in patients both with oliguria (HR per L/day of MFB 1.77, 95%CI 1.27 to 2.45) and without oliguria (HR per L/day of MFB 1.61, 95%CI 1.27 to 2.45) during the initial seven days after randomization [
19]. Our findings are consistent with these studies. Furthermore, we observed that the interaction between fluid balance and urine volume was statistically significant, and still MFB and MUV individually remained predictors of 28-day mortality.
The association between oliguria and worse outcomes in AKI patients is well recognized [
4,
22]. In our study, the survival of non-oliguric patients was significantly better when compared to oliguric patients (Figure
3), but in both groups non-survivors had significantly higher MFB (Figure
1). Similarly to other authors [
20,
25], we did not find significant differences in mortality between patients who developed early or late AKI (not shown,
P = 0.16 on log rank test) but again, non-survivors in both groups presented significantly higher MFB and lower MUV.
An interesting finding in the present study is that the use of diuretics was inversely associated with mortality, and this effect persisted after adjustment for MFB and MUV (adjusted HR 0.25, 95%CI 0.12 to 0.52), suggesting that the diuretic in itself may exert a protective effect. This differs from the FACTT study, in which post-AKI furosemide use had a protective effect on 60-day mortality on univariate analysis, but not when adjusted for fluid balance [
19]. The role of diuretics in AKI remains controversial. While three meta-analyses [
34‐
36] have demonstrated a lack of association between diuretics and mortality, only two of the included studies enrolled ICU patients. Two observational studies in ICU settings showed conflicting results. The PICARD Study Group concluded that diuretic use increased the risk of death or non-recovery of renal function (OR 1.77, 95%CI 1.14 to 2.76) [
37]. In contrast, the Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) investigators did not find a significant association between diuretic use and mortality (adjusted OR 1.21, 95%CI 0.96 to 1.5) [
38]. Loop diuretics have effects that could be potentially beneficial in preventing or minimizing the severity of AKI. They reduce the oxygen demand and prevent hypoxic damage, and furosemide has been shown to improve renal hemodynamics, attenuate ischemic-related renal angiogenesis and reduce ischemic-induced apoptosis in animal models [
39‐
41]. A pilot phase II randomized, blinded, placebo-controlled trial comparing furosemide to placebo in ICU patients with early AKI is in progress [
42]; this study aims to compare the efficacy and safety of furosemide versus placebo on the progression of AKI severity and fluid balance. The results of this trial will help us to understand better the role of diuretics in AKI in the critical care setting.
Our study has important strengths including its multicenter design that contributes to reduce practice bias. The depth of data collection permitted the exploration of the effects of duration of oliguria and diuretic use, which confirmed the results of the main analysis. Our study also extends this continuous association of fluid balance, decreased urine volume and death to critically ill adults meeting the consensus definition for AKI (RIFLE). However, we recognize some limitations. Because of the observational nature of the study, we cannot establish a causal relationship between MFB, MUV and mortality. The modest sample size precluded extensive subgroup analysis and may have resulted in underestimation of the impact of known risk factors, such as SOFA score, on multivariable analysis. We did not collect data on actual diuretic dose, but the proportion of ICU days in which diuretics were used can be considered a reasonable surrogate. It is possible that the type of fluid (that is, colloid versus crystalloid, parenteral versus enteral), aside from the volume, influences outcomes. Unfortunately, this information was not available in our own study or in previous investigations on FO [
9,
13]. We believe this is an important issue that needs to be clarified with future studies. Nevertheless, our findings are consistent across the multiple sensitivity analyses performed and the association between fluid balance, urine volume and mortality appears robust.
Participating centers
St. Bortolo Hospital, Vicenza; University of Bari, Bari; Federico II University Hospital, Naples; University of Pisa, Pisa; University Hospital Umberto I - G.M. Lancisi - G. Salesi, Torrette, Ancona; Seconda Università degli Studi di Napoli, Naples; University of Rome "La Sapienza", Rome; Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan; A.O.U.I. University of Verona, Verona; Catholic University of Sacred Heart, Rome
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The authors contributed as follows: Study conception and design - CT, FG, PP, DNC; patient enrollment and acquisition of data - NB, MI, SG, FF, MR, CBA, TB, MC, VM, PPelaia, DNC; data analysis and interpretation of the results - CT, NB, MI, DNC; Drafting of the manuscript - CT, DNC; critical revision of the manuscript - CT, FG, PP, NB, MI, SG, FF, MR, DNC; obtaining funding for the project - PP, CR. All authors have read and approved the final manuscript.